1. Scrip
  2. >>Drug Pricing

Pfizer’s Read Criticizes Rebates Amid Changing Market Dynamics

 
• By Jessica Merrill

Pfizer CEO Ian Read suggested it might be time for a new solution that would allow the pharma industry to moderate pricing based on volume without relying on rebates, criticizing a practice he said has become “less helpful” in getting cost effective solutions to patients.

Pfizer Inc. CEO Ian Read offered some negative commentary about industry’s long-standing practice of using rebates to negotiate drug prices with payers during the company’s third quarter sales and earnings call Nov. 1

“Rebates have served an important contribution to allowing negotiations on volume-related transactions,” he said, but “I think they are now...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Stock Watch: J&J’s $5bn Product Predictions Meet Investor Skepticism

 
• By Andy Smith

Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.

Big Patent Blow For Roche’s Evrysdi In India But It May Not Be Over Yet

 
• By Anju Ghangurde

Roche, which faced a high stakes patent setback for Evrysdi in India, appears to have appealed against a lower court’s ruling, which went decisively Natco’s way but also included distinct 'reservations' by the judges.

US FDA Commissioner’s Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions

 
• By Sarah Karlin-Smith

Marty Makary's role in helping negotiation the Trump Administration's second "most favored nations" drug pricing deal is raising concerns as the Trump team has suggested it would use drug pricing as a lever to impact FDA approval status or speed of drug reviews.

‘Building The Plane While Flying It’: Cell And Gene Therapy Makers Prepare For MFN Pricing, Tariffs

 
• By Mandy Jackson

It remains to be seen whether the Trump administration’s most favored nation drug pricing policy will trickle down from big pharma to small biotech, but executives said at ARM’s Cell and Gene Meeting on the Mesa that they are preparing strategies now to manage the future.

More from Scrip

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.